GENET-news
To stay informed you can subscribe to the GENET-news list.
2006-12-20 | permalink
U.S. cancels VaxGen’s $877.5 million contract to make anthrax vaccine
In a major setback for the nations efforts to counter bioterrorism, federal officials Tuesday canceled their $877.5 million contract with Brisbane-based VaxGen for an improved anthrax vaccine, because the company was behind schedule developing it. The U.S. Department of Health and Human Services sent VaxGen a letter terminating the contract, awarded in March 2004, citing the company’s failure to meet a deadline Monday for beginning a key test of the vaccine in people. The contract had been the largest issued under President Bush’s Project BioShield, a $5.6 billion program to counter bioterrorism over 10 years. Under the contract, VaxGen was to have provided 75 million doses of the vaccine, which were to be stockpiled for civilian use in case of an anthrax attack on the country.
- The Mercury News, USA: U.S. cancels VaxGen's $877.5 million contract to make anthrax vaccine
- The New York Times, USA: U.S. cancels order for 75 million doses of anthrax vaccine
- Reuters: Focus on Amgen as U.S. Congress eyes anemia drug use
- Reuters: EU expert panel rejects Novartis antifungal drug
- PharmaLive: Novartis to Provide Additional Clarification to EU Regulators on Data Supporting Approval of Mycograb for Serious Fungal Infections
Overview
News
2006-12-20 | permalink
U.S. cancels VaxGen’s $877.5 million contract to make anthrax vaccine
In a major setback for the nations efforts to counter bioterrorism, federal officials Tuesday canceled their $877.5 million contract with Brisbane-based VaxGen for an improved anthrax vaccine, because the company was behind schedule developing it. The U.S. Department of Health and Human Services sent VaxGen a letter terminating the contract, awarded in March 2004, citing the company’s failure to meet a deadline Monday for beginning a key test of the vaccine in people. The contract had been the largest issued under President Bush’s Project BioShield, a $5.6 billion program to counter bioterrorism over 10 years. Under the contract, VaxGen was to have provided 75 million doses of the vaccine, which were to be stockpiled for civilian use in case of an anthrax attack on the country.
- The Mercury News, USA: U.S. cancels VaxGen's $877.5 million contract to make anthrax vaccine
- The New York Times, USA: U.S. cancels order for 75 million doses of anthrax vaccine
- Reuters: Focus on Amgen as U.S. Congress eyes anemia drug use
- Reuters: EU expert panel rejects Novartis antifungal drug
- PharmaLive: Novartis to Provide Additional Clarification to EU Regulators on Data Supporting Approval of Mycograb for Serious Fungal Infections
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.